Skip to main content

Table 1 Baseline demographics and clinical characteristics of patients with PsA

From: Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study

 

UST (n=219)

TNFi (n=218)

Mean (SD) [95%CI] / n (%) [95%CI]

Mean (SD) [95%CI] / n (%) [95%CI]

Age, years (SD)

51.5 (13.0) [49.8; 53.2]

46.7 (12.7) [45.0; 48.4]

Male, n (%)

106 (48.4) [41.6; 55.2]

122 (56.0) [49.1; 62.7]

Female, n (%)

113 (51.6%) [44.8; 58.4]

96 (44.0%) [37.3; 50.9]

BMI, kg/m2 (SD)

28.9 (6.4) [28.0; 29.8]

27.1 (5.0) [26.5; 27.8]

Time since initial diagnosis, years (SD)

7.7 (8.5) [6.5; 8.8]

6.4 (6.7) [5.5; 7.4]

Line of bDMARD treatment, n (%)

 First-line

109 (49.8) [43.0; 56.6]

129 (59.2) [52.3; 65.8]

 Second-line

71 (32.4) [26.3; 39.1]

69 (31.7) [25.5; 38.3]

 Third-line

39 (17.8) [13.0; 23.5]

20 (9.2) [5.7; 13.8]

Cardiometabolic diseasea, n (%)

95 (43.4) [36.7; 50.2]

74 (33.9) [27.7; 40.6]

PsA characteristics, n (%)

 Axial involvementb

7 (3.2) [1.3; 6.5]

7 (3.2) [1.3; 6.5]

 Oligoarticularc

60 (27.8) [21.9; 34.3]

66 (31.0) [24.8; 37.7]

 Polyarticulard

132 (61.1) [54.3; 67.7]

135 (63.4) [56.5; 69.9]

Dactylitise, n (%)

46 (21.3) [16.0; 27.4]

62 (29.1) [23.1; 35.7]

Enthesitisf, n (%)

109 (50.7) [43.8; 57.6]

106 (48.8) [42.0; 55.7]

BSA, n (%)

 Clear/almost clear

43 (21.3) [15.9; 27.6]

58 (29.4) [23.2; 36.3]

 <3% but not clear/almost clear

18 (8.9) [5.4; 13.7]

36 (18.3) [13.1; 24.4]

 3–10%

72 (35.6) [29.0; 42.7]

72 (36.5) [29.8; 43.7]

 >10%

69 (34.2) [27.6; 41.1]

31 (15.7) [10.9; 21.6]

Psoriatic nail lesionsg, n (%)

117 (55.7) [48.7; 62.5]

96 (45.7) [38.8; 52.7]

cDAPSA, n (SD)

30.3 (21.7) [27.3; 33.3]

30.3 (20.8) [27.4; 33.2)

Swollen joint count, n (SD)

6.1 (8.5) [4.9; 7.2]

7.0 (8.7) [5.8; 8.3]

Tender joint count, n (SD)

12.7 (13.6) [10.8; 14.6]

11.8 (11.6) [10.1; 13.4]

CRP, mg/dL (SD)

1.7 (3.8) [1.1; 2.3]

1.4 (1.9) [1.1; 1.6]

FiRST scoreh

 Total score

3.5 [3.30; 3.68]

3.2 [2.99; 3.36]

 Scores ≥5, %

39.0 [34.4; 43.8]

30.1 [25.8; 34.6]

  1. Results reflect assessments for patients still under initial treatment at 3 years. Bold text indicates non-overlapping 95% CI
  2. aHypertension, myocardial infarction, congestive heart failure, stroke or transient ischemic attack, peripheral vascular disease, hyperlipidaemia, type 1 or 2 diabetes or angina pectoris
  3. bPure axial PsA is defined as having only axial involvement (presence of axial disease declared by the treating rheumatologist without a requirement for imaging)
  4. cEither TJC68 and SJC66 are both non-missing and patient has <5 swollen or <5 tender joint counts or, in case TJC68 and/or SJC66 are missing, monoarticular or oligoarticular PsA is indicated by the investigator
  5. dEither TJC68 and SJC66 are both non-missing and patient has ≥5 swollen and ≥5 tender joint counts or, in case TJC68 and/or SJC66 are missing, polyarticular PsA is indicated by the investigator
  6. eDactylitis presence detected by assessment of hands and feet
  7. fEnthesitis presence defined as Leeds Enthesitis Index ≥0
  8. gNail lesions were evaluated by recording the total number of nails of the hands and feet with PsA involvement
  9. hBased on the FAS (UST n=458 and TNFi n=471) as data were recorded at baseline only
  10. bDMARD, biologic disease-modifying antirheumatic drug; BMI, body mass index; BSA, body surface area; cDAPSA, Clinical Disease Activity in Psoriatic Arthritis; CI Confidence interval, CRP C-reactive protein, FAS Full analysis set, FiRST Fibromyalgia Rapid Screening Tool, PsA Psoriatic arthritis, SD Standard deviation, SJC66 66 swollen joint count, TJC68 68 tender joint count, TNFi Tumour necrosis factor inhibitor UST, Ustekinumab
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us